BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 25304686)

  • 21. Evidence for the complexity of microRNA-mediated regulation in ovarian cancer: a systems approach.
    Shahab SW; Matyunina LV; Mezencev R; Walker LD; Bowen NJ; Benigno BB; McDonald JF
    PLoS One; 2011; 6(7):e22508. PubMed ID: 21811625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory Mechanism of MicroRNA Expression in Cancer.
    Ali Syeda Z; Langden SSS; Munkhzul C; Lee M; Song SJ
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. microRNAs exhibit high frequency genomic alterations in human cancer.
    Zhang L; Huang J; Yang N; Greshock J; Megraw MS; Giannakakis A; Liang S; Naylor TL; Barchetti A; Ward MR; Yao G; Medina A; O'brien-Jenkins A; Katsaros D; Hatzigeorgiou A; Gimotty PA; Weber BL; Coukos G
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9136-41. PubMed ID: 16754881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum-based six-miRNA signature as a potential marker for EC diagnosis: Comparison with TCGA miRNAseq dataset and identification of miRNA-mRNA target pairs by integrated analysis of TCGA miRNAseq and RNAseq datasets.
    Sharma P; Saraya A; Sharma R
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e289-e301. PubMed ID: 29380534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic control of autophagy by microRNAs in ovarian cancer.
    Titone R; Morani F; Follo C; Vidoni C; Mezzanzanica D; Isidoro C
    Biomed Res Int; 2014; 2014():343542. PubMed ID: 24877083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.
    Loginov VI; Pronina IV; Burdennyy AM; Filippova EA; Kazubskaya TP; Kushlinsky DN; Utkin DO; Khodyrev DS; Kushlinskii NE; Dmitriev AA; Braga EA
    Gene; 2018 Jul; 662():28-36. PubMed ID: 29631007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Network analysis of microRNAs and their regulation in human ovarian cancer.
    Schmeier S; Schaefer U; Essack M; Bajic VB
    BMC Syst Biol; 2011 Nov; 5():183. PubMed ID: 22050994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying microRNA/mRNA dysregulations in ovarian cancer.
    Miles GD; Seiler M; Rodriguez L; Rajagopal G; Bhanot G
    BMC Res Notes; 2012 Mar; 5():164. PubMed ID: 22452920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist.
    Sun X; Cui M; Zhang A; Tong L; Wang K; Li K; Wang X; Sun Z; Zhang H
    J Exp Clin Cancer Res; 2016 Jan; 35():10. PubMed ID: 26762267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential role of miR-9 and miR-223 in recurrent ovarian cancer.
    Laios A; O'Toole S; Flavin R; Martin C; Kelly L; Ring M; Finn SP; Barrett C; Loda M; Gleeson N; D'Arcy T; McGuinness E; Sheils O; Sheppard B; O' Leary J
    Mol Cancer; 2008 Apr; 7():35. PubMed ID: 18442408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs.
    Wu M; Jolicoeur N; Li Z; Zhang L; Fortin Y; L'Abbe D; Yu Z; Shen SH
    Carcinogenesis; 2008 Sep; 29(9):1710-6. PubMed ID: 18356149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated microRNA and mRNA signatures in peripheral blood lymphocytes of familial epithelial ovarian cancer.
    Dou YD; Huang T; Wang Q; Shu X; Zhao SG; Li L; Liu T; Lu G; Chan WY; Liu HB
    Biochem Biophys Res Commun; 2018 Jan; 496(1):191-198. PubMed ID: 29307835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
    Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N
    Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS.
    Fu X; Cui Y; Yang S; Xu Y; Zhang Z
    Tumour Biol; 2016 May; 37(5):6477-83. PubMed ID: 26631045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome-wide analysis of microRNA and mRNA expression signatures in cancer.
    Li MH; Fu SB; Xiao HS
    Acta Pharmacol Sin; 2015 Oct; 36(10):1200-11. PubMed ID: 26299954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction of integrated microRNA and mRNA immune cell signatures to predict survival of patients with breast and ovarian cancer.
    Ray M; Ruffalo MM; Bar-Joseph Z
    Genes Chromosomes Cancer; 2019 Jan; 58(1):34-42. PubMed ID: 30285311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miRNAs and ovarian cancer: An overview.
    Deb B; Uddin A; Chakraborty S
    J Cell Physiol; 2018 May; 233(5):3846-3854. PubMed ID: 28703277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of microRNAs in ovarian cancer initiation and progression.
    Li SD; Zhang JR; Wang YQ; Wan XP
    J Cell Mol Med; 2010 Sep; 14(9):2240-9. PubMed ID: 20345848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent trends in targeting miRNAs for cancer therapy.
    Shah V; Shah J
    J Pharm Pharmacol; 2020 Dec; 72(12):1732-1749. PubMed ID: 32783235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA expression and identification of putative miRNA targets in ovarian cancer.
    Dahiya N; Sherman-Baust CA; Wang TL; Davidson B; Shih IeM; Zhang Y; Wood W; Becker KG; Morin PJ
    PLoS One; 2008 Jun; 3(6):e2436. PubMed ID: 18560586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.